Top Blue Chip Stocks For 2019

&l;p&g;&l;img class=&q;dam-image shutterstock size-large wp-image-1106738453&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1106738453/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Shutterstock

What if I told you there&a;rsquo;s a way you can buy your favorite blue chips and get a dividend &l;i&g;up to 6 times bigger&l;/i&g; than what these stocks pay today?

Let&a;rsquo;s be honest: with an income stream like that, backed by household names like &l;b&g;Pfizer &l;/b&g;and &l;b&g;AT&a;amp;T&l;/b&g;&a;mdash;more on these two stocks below&a;mdash;you&a;rsquo;d leap at the chance, right?

The truth is, you&a;rsquo;d be crazy not to.

Well, now you can. And today I&a;rsquo;m going to show you exactly how to do it&a;mdash;and 2 quick moves to get you there instantly.

&l;b&g;Like Buying Cheap in 2009 &a;hellip; and Knowing What Happens Next&l;/b&g;

Funny thing is, for a brief, shining moment in the not-so-distant past (early March 2009), many blue chips actually &l;i&g;did&l;/i&g; deliver payouts of 7%, 10% and more.

Top Blue Chip Stocks For 2019: Freshpet, Inc.(FRPT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Freshpet (NASDAQ:FRPT) – Research analysts at William Blair reduced their Q2 2018 earnings estimates for shares of Freshpet in a research note issued to investors on Monday, May 7th. William Blair analyst J. Andersen now expects that the company will post earnings per share of ($0.09) for the quarter, down from their prior forecast of ($0.04). William Blair also issued estimates for Freshpet’s Q4 2018 earnings at $0.10 EPS and FY2018 earnings at ($0.07) EPS.

  • [By Max Byerly]

    Shares of Freshpet Inc (NASDAQ:FRPT) have been assigned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $20.60.

  • [By Jon C. Ogg]

    Freshpet Inc. (NASDAQ: FRPT) was maintained as Neutral but the target price was raised to $36 from $32 at Credit Suisse.

    Harpoon Therapeutics Inc. (NASDAQ: HARP) was started as Outperform and assigned a $23 price target (versus a $17.01 close) at Wedbush Securities.

  • [By Motley Fool Transcribers]

    Freshpet Inc  (NASDAQ:FRPT)Q4 2018 Earnings Conference CallFeb. 26, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top Blue Chip Stocks For 2019: Alaska Air Group, Inc.(ALK)

Advisors’ Opinion:

  • [By Adam Levine-Weinberg]

    The oil rally has cooled off this month, over recent reports that have alleviated investors’ worries about a serious oil shortage. Lower jet fuel prices should help all of the airlines, but two could benefit disproportionately: Spirit Airlines (NYSE:SAVE) and Alaska Air (NYSE:ALK).

  • [By Adam Levine-Weinberg]

    The last couple of years have not been kind to JetBlue Airways (NASDAQ:JBLU) and Alaska Air Group (NYSE:ALK). Rising fuel prices have pinched profitability across the U.S. airline industry, but due to competitive dynamics and other factors, JetBlue and Alaska have had more trouble offsetting these cost headwinds than some other carriers.

  • [By Todd Shriber, ETF Professor]

    The analyst highlighted American Airlines Group Inc. (NASDAQ: AAL), Delta Airlines Inc. (NYSE: DAL), Southwest Airlines Co. (NYSE: LUV) and Alaska Air Group Inc. (NASDAQ: ALK) as among the industry's best-positioned names. The quartet combines for over 38 percent of JETS' roster.

Top Blue Chip Stocks For 2019: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By ]

    Some of my readers may know Sarepta (Nasdaq: SRPT) well. This $9 billion gene-therapy company already has an FDA-approved product. Exondys 51, the first-ever FDA-approved treatment for a rare but deadly genetic disease called Duchenne muscular dystrophy (DMD), is already on the market. And just last month, the FDA granted priority review for SRPT’s second treatment for DMD, golodirsen, for DMD patients with a different genetic mutation.

  • [By WWW.GURUFOCUS.COM]

    For the details of ETF Portfolio Partners, Inc.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=ETF+Portfolio+Partners%2C+Inc.

    These are the top 5 holdings of ETF Portfolio Partners, Inc.Vanguard Total Stock Market (VTI) – 194,472 shares, 17.91% of the total portfolio. Shares added by 1.13%iShares Core U.S. Aggregate Bond (AGG) – 254,189 shares, 17.72% of the total portfolio. Shares added by 3.15%iShares Russell 1000 (IWB) – 98,181 shares, 9.78% of the total portfolio. Shares added by 0.56%Vanguard FTSE Developed Markets (VEA) – 322,914 shares, 9.08% of the total portfolio. Shares added by 1.20%iShares S&P 500 Value (IVE) – 108,531

  • [By Keith Speights]

    Three biotech stocks — Solid Biosciences (NASDAQ:SLDB), Sarepta Therapeutics (NASDAQ:SRPT), and Heron Therapeutics (NASDAQ:HRTX) — soared this week by 30% or more thanks to news that brought smiles to investors’ faces. Here’s what drove these stocks higher and whether or not they’re smart picks to buy now.

  • [By Angelica LaVito]

    CAMBRIDGE, Mass.,June 19, 2018 (GLOBE NEWSWIRE) –Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced that at the Company’s R&D Day,Jerry Mendell, M.D. of Nationwide Children’s Hospital presented positive preliminary results from its Phase 1/2a gene therapy clinical trial assessing AAVrh74.MHCK7.micro-Dystrophin in individuals with Duchenne muscular dystrophy (DMD). Dr. Mendell presented the following preliminary data on the first three patients enrolled in the study:

Top Blue Chip Stocks For 2019: UFP Technologies Inc.(UFPT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    UFP Technologies (NASDAQ: UFPT) and China XD Plastics (NASDAQ:CXDC) are both small-cap industrial products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

  • [By Ethan Ryder]

    Media coverage about UFP Technologies (NASDAQ:UFPT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. UFP Technologies earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned headlines about the industrial products company an impact score of 47.0533500754779 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Logan Wallace]

    China XD Plastics (NASDAQ: CXDC) and UFP Technologies (NASDAQ:UFPT) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Leave a Reply

Your email address will not be published. Required fields are marked *